Business Wire·Nov 10, 2026, 4:01 PM ET

Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update

Gossamer Bio submitted a New Drug Application for seralutinib to treat pulmonary arterial hypertension to the U.S. FDA in September 2026.
A structured private placement secured $25 million upfront with up to $125 million additional committed capital pending FDA acceptance of the NDA.
The company completed a 1-for-80 reverse stock split in September 2026 to regain Nasdaq compliance.
Gossamer reacquired worldwide rights to seralutinib from Chiesi in July 2026, receiving a $5 million payment while retaining royalty obligations.
Cash, cash equivalents, Marketable securities totaled $51.2 million as of September 30, 2026.
Revenue from contracts with collaborators reached $38.4 million for the quarter, driven by the termination of the Chiesi collaboration.
Research development expenses decreased to $18.8 million for the quarter due to reduced clinical trial costs.
The company reported a net loss of $48.1 million, or $7.36 per share, for the three months ended September 30, 2026.
Management aims to support FDA review prepare for a potential seralutinib commercial launch in 2027.